- Home
- RSLS vs TCRT Comparison
RSLS vs TCRT Comparison
Compare RSLS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- TCRT
- Stock Information
- Founded
- RSLS 2002
- TCRT 1998
- Country
- RSLS United States
- TCRT United States
- Employees
- RSLS N/A
- TCRT N/A
- Industry
- RSLS Medical/Dental Instruments
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- TCRT Health Care
- Exchange
- RSLS Nasdaq
- TCRT Nasdaq
- Market Cap
- RSLS 4.5M
- TCRT 3.8M
- IPO Year
- RSLS 2007
- TCRT N/A
- Fundamental
- Price
- RSLS $2.39
- TCRT $4.99
- Analyst Decision
- RSLS Hold
- TCRT
- Analyst Count
- RSLS 1
- TCRT 0
- Target Price
- RSLS N/A
- TCRT N/A
- AVG Volume (30 Days)
- RSLS 4.4M
- TCRT 49.7K
- Earning Date
- RSLS 08-13-2025
- TCRT 08-13-2025
- Dividend Yield
- RSLS N/A
- TCRT N/A
- EPS Growth
- RSLS N/A
- TCRT N/A
- EPS
- RSLS N/A
- TCRT N/A
- Revenue
- RSLS $7,175,000.00
- TCRT $11,000.00
- Revenue This Year
- RSLS $52.80
- TCRT $5,680,500.00
- Revenue Next Year
- RSLS N/A
- TCRT N/A
- P/E Ratio
- RSLS N/A
- TCRT N/A
- Revenue Growth
- RSLS N/A
- TCRT 83.33
- 52 Week Low
- RSLS $2.23
- TCRT $1.31
- 52 Week High
- RSLS $347.86
- TCRT $6.80
- Technical
- Relative Strength Index (RSI)
- RSLS 38.10
- TCRT 66.12
- Support Level
- RSLS $2.37
- TCRT $4.72
- Resistance Level
- RSLS $2.73
- TCRT $5.24
- Average True Range (ATR)
- RSLS 0.17
- TCRT 0.46
- MACD
- RSLS 0.21
- TCRT -0.02
- Stochastic Oscillator
- RSLS 13.33
- TCRT 66.89
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.